The linked FDA records tie Abbott Vascular, Inc. to a single premarket approval number, P960043, and to the Perclose device line. The original approval, dated April 30, 1997, covers the PROSTAR 9 FR. Percutaneous Vascular Surgical (PVS) System, described in the approval order as consisting of the PROSTAR PVS device in 9 and 11 French sizes with accessories including a pre-dilator, a Perclose knot pusher, a PROSTAR transition guidewire and a Perclose arterial tamper. Later supplements under the same PMA name the Perclose ProGlide and Perclose ProStyle systems. [4][1][2]
The applicant and the PMA it holds
Abbott Vascular, Inc. appears as the applicant on each of the four supplied PMA records, all under P960043 and product code MGB, with the generic name Device, hemostasis, vascular, and Cardiovascular advisory committee assignment. The filing address given in the records is 400 Saginaw Dr., Redwood, CA 94063; that is a filing address in the data, not a verified headquarters. A separate FDA summary of safety and effectiveness data for P960043/S118 lists the applicant as Abbott Medical at 3200 Lakeside Drive, Santa Clara, CA 95054, so the corporate naming across filings is not uniform. [1][4][9]
The supplied collection contains four linked PMA records as of the snapshot date. Decision counts across that collection are three OK30 and one APPR; the smaller record sample of four rows carries the same three-to-one split. These are counts of supplied filings, not measures of total portfolio, sales or safety performance. [1][2][3][4]
Documented products and components
The 1997 approval order describes the PROSTAR PVS System as the PROSTAR PVS device in 9 and 11 French sizes plus a PROSTAR pre-dilator, a Perclose knot pusher, a PROSTAR transition guidewire and a Perclose arterial tamper. The stated indication concerns percutaneous delivery of sutures for closing the common femoral artery access site and reducing time to hemostasis and ambulation for patients who have undergone interventional procedures using 8 to 11 French sheaths. [4]
Abbott's own product pages describe the Perclose ProGlide Suture-Mediated Closure System as part of the Perclose family and state that it is intended for suture-mediated closure at both femoral arterial and venous access sites. The Perclose ProStyle page describes the ProStyle Suture-Mediated Closure and Repair System as the next-generation design of the ProGlide system, with each device delivering a pretied suture to the femoral access site. Both pages direct readers to labeling for indications, contraindications, warnings, precautions and adverse events. [6][10]
Recent supplement activity
Three 30-Day Notice supplements under P960043 were decided in late 2026, each coded OK30 with supplement reason Process Change - Manufacturer/Sterilizer/Packager/Supplier. S137, received August 26, 2026 and decided September 24, 2026, covers automation of an existing suture trimmer manufacturing process. S138, received September 21, 2026 and decided October 26, 2026, covers an alternate supplier and a different surface-finishing process for the e-guide tube and suture trimmer sheath. S139, received October 16, 2026 and decided November 4, 2026, adds a cuff swaging location in another suite of the same facility. [3][2][1]
These entries are manufacturing and supplier notices rather than new clinical approvals, and the linked FDA records do not describe any change to indications for the devices named in them. The 2023 SSED for P960043/S118 records a June 2, 2023 approval order and states that the applicant's manufacturing facilities were inspected and found in compliance with the Quality System regulation. [1][9]
Reading the record carefully
The FDA database pages retrieved for S138 and S139 supply only navigation and agency boilerplate in the captured text, so the substantive supplement details come from the structured API records. The Perclose pages are published by Abbott and describe company product positioning; statements such as the family being a comprehensive, proven solution for hemostasis management are Abbott's characterization, not an independent finding. No supplied source establishes ownership by a parent company, commercial availability, customer base or clinical performance. [5][7][6][8]




